Ultragenyx Pharmaceutical Inc.
RAREHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Ultragenyx Pharmaceutical Inc. focuses on Biotechnology services and products. Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare. At a $2.88B market cap, Ultragenyx Pharmaceutical Inc. ranks as a mid-cap company within healthcare. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Market Cap
$2.88B
Beta
0.31
P/E (TTM)
—
P/E (Fwd)
18.89
EPS (TTM)
$-5.91
EPS (Fwd)
$1.55
ROE
—
ROA
-25.4%
Cash
$413.0M
Total Debt
$1.20B
Free CF
-$219.1M
52W Change
11.3%
Annual Financials
Cash vs Debt
On the balance sheet, RARE has $413.0M in cash with $1.20B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Free cash flow is running at -$219.1M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $363.3M (2022) to $673.0M (2025), reflecting a 85% increase over the period.
RARE's low beta indicates it tends to be less volatile than the broader market, which may suit investors seeking more stable price behavior. Negative free cash flow means the company is currently spending more than it generates, which may require future fundraising or debt if the trend continues. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Ultragenyx Pharmaceutical Inc.'s trajectory.